David D Tran MD PhD

Neuro-Oncology

Co-Director, USC Brain Tumor Center Chief, Neuro-Oncology Professor of Neurosurgery and Neurology University of Southern California Keck School of Medicine

Join to View Full Profile

1520 San Pablo StSte 3800Los Angeles, CA 90033
Phone+1 323-442-5720

Summary

David Tran, MD, is an oncology specialist with a subspecialty in neuro-oncology located in Los Angeles, CA. He completed a fellowship in Hematology and Medical Oncology and a residency in Internal Medicine at the Washington University/B-JH/SLCH Consortium. He also holds a PhD in Biomedical Sciences from the Mayo Clinic College of Medicine. Dr. Tran is a Co-Director at the USC Brain Tumor Center and serves as the Chief of Neuro-Oncology at Keck Medicine. He is experienced in neuro-oncology, tumor immunotherapy, and biomedical research. His recent publications include work on GBM and immunotherapy, and he has participated in clinical trials ranging from breast cancer therapies to glioblastoma treatments. Dr. Tran has been recognized with the CMS Meaningful Use Stage 1 Certification in 2012.

Clinical Expertise

Neuro-oncology, Tumor immunotherapy, Biomedical research

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
Mayo Clinic College of MedicineClass of 2005
Mayo Clinic College of MedicinePhD, Biomedical Sciences, 2003

Certifications & Licensure

CA State Medical License 2023 - 2027
FL State Medical License 2015 - 2023
MO State Medical License 2007 - 2016
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
Completed
Early Phase 1
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Start of enrollment: 2012 Dec 01
Terminated
Phase 4
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 21
COMPLETED
PHASE3
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 Jun 19
TERMINATED
PHASE2
MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2013 Aug 13
Completed
Phase 1
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Start of enrollment: 2016 Dec 19
Terminated
Phase 2
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma Start of enrollment: 2019 May 20
Terminated
Phase 2
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Start of enrollment: 2020 Sep 26
RECRUITING
PHASE1, PHASE2
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Start of enrollment: 2018 Feb 23
ACTIVE_NOT_RECRUITING
PHASE2
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Start of enrollment: 2015 Aug 05
COMPLETED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma.
William G Breen, J G Dixon, S K Anderson, J N Sarkaria, P D Brown
Neuro-Oncology. 2025-06-28
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Dongjiang Chen, Son B Le, Ashley P Ghiaseddin, Harshit Manektalia, Ming Li
Med. 2025-06-03
1 citations
The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields.
Dongjiang Chen, Son B Le, Harshit Manektalia, Tianyi Liu, Tarun E Hutchinson
Cancer Research. 2025-01-15

Press Mentions

Electric Fields May Supercharge the Immune System to Fight Deadly Brain CancerJune 23rd, 2025
HMN 2025: How Could Electrical Fields Supercharge Immune Assault on the Deadliest Type of Mind Cancer?June 11th, 2025
Can Electric Fields Supercharge the Immune Response Against the Most Aggressive Brain Cancer?June 9th, 2025
Join now to see all